Drug Research

AstraZeneca has agreed to invest $2 billion in Summit Therapeutics to support the development of ivonescimab and explore new cancer treatment combinations involving antibody-drug…
Read More...

Sentynl Therapeutics, a U.S.-based biopharmaceutical company and wholly owned subsidiary of Zydus Lifesciences, has entered into an option and license agreement with clinical-stage rare…
Read More...

Latus Bio, Inc. has secured $97 million in Series A financing to accelerate the development of its gene therapy pipeline, marking a significant milestone for the early-stage biotech…
Read More...

The Medicines and Healthcare products Regulatory Agency (MHRA) and National Institute for Health and Care Excellence (NICE) have unveiled a new collaborative framework aimed at speeding…
Read More...

Novartis has announced a strategic agreement with Synnovation Therapeutics, LLC to acquire SNV4818, an investigational oral therapy designed to treat hormone receptor-positive,…
Read More...

The U.S. Food and Drug Administration has announced a new regulatory initiative aimed at accelerating the development of biosimilar medicines while reducing costs for drug manufacturers…
Read More...

Clinical-stage biotechnology company Insilico Medicine and pharmaceutical commercialization group China Medical System Holdings have announced a multi-project collaboration aimed at…
Read More...

China’s National Medical Products Administration (NMPA) has approved ENHERTU® (trastuzumab deruxtecan) for the treatment of adult patients with locally advanced or metastatic…
Read More...

Synaffix B.V., a Lonza company, and Sidewinder Therapeutics have entered into a multi-target licensing agreement aimed at developing first-in-class bispecific antibody-drug conjugate…
Read More...

The U.S. Food and Drug Administration (FDA) has approved Novartis’ Itvisma® (onasemnogene abeparvovec-brve) for children aged two years and older, as well as teens and adults, living…
Read More...

Algen Biotechnologies has entered a multi-target partnership with AstraZeneca aimed at speeding up the discovery of new therapeutic targets in immunology. The collaboration will…
Read More...

Taysha Gene Therapies announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to TSHA-102, its intrathecally delivered AAV9 gene therapy…
Read More...

Boehringer Ingelheim announced that its drug HERNEXEOS (zongertinib tablets) has received approval from China’s National Medical Products Administration (NMPA) as a monotherapy…
Read More...

Since announcing their partnership in April 2025, AstraZeneca and Revna Biosciences have made significant strides in improving lung cancer care across Ghana, from early diagnosis to…
Read More...

Ferrer has announced that its investigational therapy FNP-223, developed to treat progressive supranuclear palsy (PSP), has received Fast Track designation from the U.S. Food and Drug…
Read More...

Eli Lilly and Company and Verve Therapeutics, Inc., a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease, announced a definitive agreement for…
Read More...

Orion and Glykos announce the extension of their research collaboration and licensing agreement for the development of next-generation ADCs Orion Corporation and Glykos Finland Oy…
Read More...

AbbVie announced that the U.S. Food and Drug Administration (FDA) approved a label expansion for MAVYRET (glecaprevir/pibrentasvir), an oral pangenotypic direct acting antiviral (DAA)…
Read More...

Merck, known as MSD outside of the United States and Canada, announced the U.S. Food and Drug Administration (FDA) has approved ENFLONSIA™ (clesrovimab-cfor) for the prevention of…
Read More...

Vividion Therapeutics, Inc. (Vividion), a clinical-stage biopharmaceutical company, and a wholly owned and independently operated subsidiary of Bayer AG, announced it has secured…
Read More...